 Telegraph.co.uk |
GSK and Theravance to file COPD/asthma drug
The Pharma Letter For asthma, GSK plans to submit an application in Europe in mid-2012 and will continue discussions with the Food and Drug Administration on the regulatory requirements for a US asthma indication. Despite some mixed clinical trial results with Relovair … GSK, Theravance report completion of Relovair studies in COPD and asthma GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies … Theravance Falls Most in 3 Years After Glaxo Drug Fails |
View full post on asthma – Google News